The J-Curve Between Blood Pressure and Coronary Artery Disease or Essential Hypertension Exactly How Essential? by Messerli, Franz H. & Panjrath, Gurusher S.
T
a
i
(
e
h
p
t
a
w
a
t
b
n
c
c
p
H
t
F
U
†
M
B
G
2
Journal of the American College of Cardiology Vol. 54, No. 20, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PVIEWPOINT AND COMMENTARY
The J-Curve Between Blood Pressure and Coronary
Artery Disease or Essential Hypertension
Exactly How Essential?
Franz H. Messerli, MD,* Gurusher S. Panjrath, MD†
New York, New York; and Baltimore, Maryland
The topic of the J-curve relationship between blood pressure and coronary artery disease (CAD) has been the
subject of much controversy for the past decades. An inverse relationship between diastolic pressure and ad-
verse cardiac ischemic events (i.e., the lower the diastolic pressure the greater the risk of coronary heart disease
and adverse outcomes) has been observed in numerous studies. This effect is even more pronounced in patients
with underlying CAD. Indeed, a J-shaped relationship between diastolic pressure and coronary events was docu-
mented in treated patients with CAD in most large trials that scrutinized this relationship. In contrast to any
other vascular bed, the coronary circulation receives its perfusion mostly during diastole; hence, an excessive
decrease in diastolic pressure can significantly hamper perfusion. This adverse effect of too low a diastolic pres-
sure on coronary heart disease leaves the practicing physician with the disturbing possibility that, in patients at
risk, lowering blood pressure to levels that prevent stroke or renal disease might actually precipitate myocardial
ischemia. However, these concerns should not deter physicians from pursuing a more aggressive control of hy-
pertension, because currently blood pressure is brought to recommended target levels in only approximately
one-third of patients. (J Am Coll Cardiol 2009;54:1827–34) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.073l
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the term “essential hypertension” was coined by Frank (1)
lmost a century ago by stating “Because in this disease the
ncrease in tone of the small arteries in the whole body
which leads to an increase in blood pressure) is the primary
vent . . . I will, in the following, name this disease, essential
ypertension (essentielle Hypertonie).” The concept of hy-
ertension being essential (i.e., serving to force blood
hrough sclerotic arteries to the target organs) remained
live and well into the 1970s, and statements like “For aught
e know, the hypertension might be a compensatory mech-
nism that should not be tampered with even were it certain
hat we could control it” (2) and “May not the elevation of
lood pressure be a natural response to guarantee a more
ormal circulation to the heart, brain and kidneys” (3)
ontinued to appear in published reports and spook physi-
ians. This concept also instigated fear that, in susceptible
atients, blood pressure (BP) could be lowered too much.
ence, the reluctance of many physicians to expose patients
o antihypertensive therapy is not surprising, because abrupt
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niversity, College of Physicians and Surgeons, New York, New York; and the
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009, accepted May 6, 2009.owering of BP in hypertensive emergencies, paradoxically,
an increase target organ disease such as renal failure,
ncephalopathy, and coronary ischemia and even directly
ause heart attacks, stroke, and death (4). Gradually, how-
ver, the pendulum began to swing toward the other
xtreme, and the dictum, “the lower the better,” became the
eitmotiv for most physicians treating hypertension. The
arge, thorough meta-analysis of Lewington et al. (5)
orroborated and amplified this concept by stating that
usual BP is strongly and directly related to vascular (and
verall) mortality without any evidence of a threshold down
o at least 115/75 mm Hg.” Statements like these threatened
o put an end to the “essentiality” of essential hypertension.
he J-Curve Concept
ggressive BP-lowering notwithstanding, a concept that
ever quite vanished from the published reports and sur-
aced in many randomized trials was the J-curve phenom-
non. The question was not whether there was a J-curve—
bviously there had to be, because a BP of 0 encompasses a
00% mortality—the question was whether such a J-curve
id occur within a “physiologic” range of BP. Because the
oronary arteries are perfused predominantly during dias-
ole, a J-curve, if any, should be most apparent for diastolic
ressure and coronary events.
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The J-Curve November 10, 2009:1827–34Three decades ago Stewart (6)
cautioned against too-aggressive
antihypertensive therapy, be-
cause cardiovascular complica-
tions might be increased with a
fall in BP, especially diastolic
blood pressure (DBP). On com-
paring the DBP of 169 hyperten-
sive patients taking antihyper-
tensive agents over a 6-year
period, a DBP of 90 mm Hg
was associated with a 5-fold
greater risk of myocardial infarc-
tion (MI) compared with a DBP
of 100 to 109 mm Hg (6). One
decade later, Cruickshank et al.
(7), in 902 patients with
moderate-to-severe hyperten-
sion, reported a strong J-curve
elationship between death from MI and treated DBP only
n patients with coronary artery disease (CAD). The nadir
f the J-curve in DBP was at 85 to 90 mm Hg, with an
ncrease of mortality from MI on either side of this range. In
atients without CAD, there was no J-curve or J-curve
elationship with systolic pressure in those with or without
AD. In 1992, Farnett et al. (8) thoroughly analyzed a
eries of large hypertension studies and demonstrated a
onsistent J-shaped relationship for cardiac events and DBP
ut not between treated BP and stroke or systolic pressure
nd cardiac events. Emphasizing the organ-specific effect of
ow DBP, the authors commented that this might “leave a
linician with the uncomfortable choice of whether to
revent stroke or renal disease at the expense of coronary
eart disease or vice versa.”
athophysiologic Consideration:
oronary Flow and BP
he coronary circulation is unique in that most of coronary
lood flow to the left ventricle (LV) occurs in diastole.
uring systole, the contracting LV myocardium compresses
ntramyocardial vessels and obstructs its own blood flow. At
eak systole, there is even a backflow in the coronary
rteries, particularly in the intramural and small epicardial
rteries (9). Coronary perfusion pressure is the pressure
radient between the coronary arteries and the right atrium
r LV in diastole. When coronary perfusion pressure is
owered to 40 to 50 mm Hg, the so-called pressure at 0 flow,
iastolic blood flow in the coronaries ceases (10).
Normal epicardial coronary arteries are conductance ves-
els and do not offer any significant resistance to blood flow.
ven at the highest level of blood flow, there is no
etectable pressure drop along the length of human epicar-
ial arteries (11). These arteries branch into a series of
rterioles in which a larger pressure drop occurs. The arterioles
Abbreviations
and Acronyms
BP  blood pressure
CAD  coronary artery
disease
CVD  cardiovascular
disease
DBP  diastolic blood
pressure
ECG  electrocardiogram
LV  left ventricle/
ventricular
LVH  left ventricular
hypertrophy
MI  myocardial infarction
SBP  systolic blood
pressurehen arborize into a dense capillary network of approximately a,000/mm2 to ensure that each myocyte is adjacent to a
apillary. This capillary density is reduced in the presence of left
entricular hypertrophy (LVH). There is no functional evi-
ence of enhanced coronary collateral circulation in patients
ith LVH as was previously believed (12).
Autoregulation ensures relatively constant myocyte per-
usion over a wide perfusion pressure range of 45 to 125 mm
g (13). It follows that autoregulation will compensate for
he various degrees of proximal epicardial coronary obstruc-
ion, ensuring optimal distal blood flow to the myocytes.
owever, in patients with CAD, autoregulation can be
ompromised. A fall in DBP might lower perfusion pressure
istal to a stenosis below the critical level at which autoreg-
lation is effective, thereby compromising myocardial per-
usion, intensifying myocardial ischemia, and causing an
ncrease in LV filling pressures, which in turn further
educes the perfusion gradient. Longstanding hypertension
nd LVH narrow the range of coronary arterial autoregu-
ation, especially in the subendocardium (14). In patients
ith LVH, subendocardial ischemia might occur even in
he absence of stenosis. It follows that a DBP range
onsidered to be “physiologic” might precipitate the vicious
ycle of myocardial ischemia and infarction in patients with
ompromised coronary flow and concomitant LVH.
ffect of BP-Lowering
n patients with hypertension and established LVH, rapidly
owering the DBP to levels of between 85 and 90 mm Hg
as reported to cause ischemic T-wave changes on the
lectrocardiogram (ECG) without symptoms of ischemia
15). In the Skaraborg hypertension project, Lindblad et al.
16) demonstrated that lowering of DBP in hypertensive
en with ischemic/hypertrophic ECGs increased the risk
or a first MI. The opposite was true in men with normal
CGs.
Not surprisingly, on simultaneous ECG and ambulatory
P monitoring of patients over a 24-h period, Owens and
’Brien (17) reported a temporary relationship between
schemic events and diastolic (rather than systolic) hypotension
n 13 of 14 instances. The ST-segment events were signifi-
antly associated with preceding hypotensive events. Similarly,
erlo et al. (18) studied 484 elderly men taking antihyperten-
ive medications over a 10-year follow-up and found the risk of
n ischemic cardiac event to be higher (more than 2-fold) in
en who were taking antihypertensive drugs than in those
ho were not. In patients with DBP 90 mm Hg the risk of
n ischemic cardiac event associated with taking antihyperten-
ive drugs was 4 times higher and remained significantly high
fter adjustment for other cardiovascular risk factors. These
ndings support the concept of a J-shaped curve for risk of MI
n relation to treated DBP (18).
enial of a J-Curve
espite evidence to the contrary in their own studies, some
uthors have denied the existence of a J-curve. Glynn et al.
(
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November 10, 2009:1827–34 The J-Curve19), in the Physician’s Health Study and the Women’s
ealth Study, evaluated the risk for MI, stroke, coronary artery
ypass, angioplasty, and cardiovascular death associated with
oth systolic blood pressure (SBP) and DBP in 22,071 men
nd 39,876 women with a median follow-up duration of 13.0
nd 6.2 years, respectively. Investigators claimed an absence of
lateau or J-curve in both populations and a lower event rate
ssociated with lower levels of blood. However, upon closer
crutiny, prominent J-curves can be observed in relation to
BP (Figs. 1 and 2 in Glynn et al. [19]).
In the HOT (Hypertension Optimal Treatment) study,
ansson et al. (20) and Cruickshank (21) scrutinized the
igh-risk patient group with coronary ischemia. He found
hat there was a 22% increase in the risk of MI when the
BP was 80 mm Hg compared with 85 mm Hg. The
elationship between MI and DBP was J-shaped in patients
ith coronary ischemia but not in nonischemic patients.
In the Cardiovascular Health Study, Psaty et al. (22)
oncluded that “the association between BP level and
ardiovascular disease (CVD) risk was generally linear;
pecifically, there was no evidence of a J-shaped relation-
hip.” Yet again, on closer scrutiny, a J-shaped relationship
etween DBP and MI is observed with a nadir at 69 mm
g. Additionally, a similar relationship was observed be-
ween DBP and risk of death in all 4,902 subjects.
echanism(s) of the J-Curve Phenomenon
hree pathophysiologic mechanisms have been proposed to
xplain the existence of a J-curve: 1) low DBP could be an
piphenomenon to coexisting or underlying poor health or
hronic illness leading to increasing morbidity and mortality
reverse causality); 2) low DBP could be caused by an
ncreased pulse pressure reflecting advanced vascular disease
nd stiffened large arteries; and 3) over-aggressive antihy-
ertensive treatment could lead to too-low DBP and thus
ypoperfusion of the coronaries resulting in coronary events.
everse causality. Chronic disease states such as neo-
lasms, chronic infection, malnutrition, and ischemic and
onischemic LV dysfunction can lead to low BP (23–26).
he National Institute on Aging-sponsored EPESE
Established Populations for Epidemiologic Studies of the
lderly) studied more than 10,000 elderly patients over 5 years
o assess the relationship between BP and cause-specific
ortality. At 2 years, SBP showed a J-curve relationship with
ll-cause mortality. All-cause mortality, CVD, and cancer
ortality were highest in the low-DBP group (75 mm Hg).
hus, comorbidities such as cancer and thus low weight and
ypotension were the confounding factors that obscured the
rue relationship of BP and mortality.
A meta-analysis by Boutitie et al. (27) on 40,233 hyper-
ensive patients from 7 randomized trials showed a positive
-curve relationship between DBP as well as SBP and both
atal cardiovascular and noncardiovascular mortalities. The
uthors concluded that the J-curve relationship is possibly
ttributed to poor health, because it was independent of gither treatment or type of events. The NHANES (Na-
ional Health and Nutrition Examination Survey) showed a
-curve between DBP and cardiovascular mortality in pa-
ients older than 55 years, even after correcting for regression
ilution bias and removing confounders, such as patients with
erious illnesses (28). In contrast, in the INVEST (Interna-
ional Verapamil-Trandolapril) study neither body mass index
or diagnosis of cancer interacted with the J-curve between
iastolic pressure and primary outcome, arguing against weight
oss/cachexia or malignancies as being the cause of this obser-
ation (29). Thus, although the role of reverse causality in
ausing a J-curve phenomenon or “epiphenomenon” cannot be
uled out, evidence supporting it as the only or the major
ontributor is unconvincing.
ncrease in pulse pressure. Increase in pulse pressure has
een shown to increase the risk of a coronary event; in fact, an
ncreased pulse wave velocity is a powerful independent pre-
ictor of cardiovascular events (30), specifically of coronary
eart disease (31). Vaccarino et al. (32) found that a 10-mm
ncrease in pulse pressure was associated with a 12% increase in
oronary heart disease risk in 2,000 elderly patients followed up
or 10 years. A recent subanalysis of the Systolic Hypertension
n the Elderly Program revealed that a drug-induced decrease
f merely 5 mm Hg in diastolic pressure significantly increased
ardiovascular events (33). Benetos et al. (34), in a large French
opulation (n  77,023), found men with systolic hyperten-
ion to be at greater risk when their diastolic pressure was
elow normal than when they had a mild-to-moderate increase
n diastolic pressure. Similarly, Glynn et al. (35) found pulse
ressure to be the best simple predictor for cardiovascular
ortality in a large (n  9,431) elderly population study
rganized by the National Institute of Aging.
In the Framingham cohort, in patients free of CVD,
annel et al. (36) found an increase in both crude as well as
ge- and risk-factor–adjusted rate of CVD at low DBP
80 mm Hg). However, this increase in the rate of CVD
as accompanied by increased SBP. The authors concluded
hat the excess CVD risk and mortality at low DBP is
ttributable to individuals with a concomitant increase in SBP
i.e., “an increased pulse pressure”). The CVD risk became
ubstantial at pulse pressures of 45 mm Hg without an
ncrease in nonfatal CVD risk at low pulse pressures. Interest-
ngly, for a fixed systolic pressure, diastolic pressures below 80
m Hg were associated with increased cardiovascular risk.
Also, in a pooled analysis of individual patient data from
large trials involving approximately 8,000 patients, Bla-
her et al. (37) showed that a 10-mm wider pulse pressure
ncreased the risk of major cardiovascular complications. At
ny level of SBP end points also increased with lower DBP.
The fact that, in several major studies of populations of
ypertensive patients, pulse pressure was documented to be
n independent risk factor for coronary heart disease irre-
pective of systolic pressure leads to the conclusion that
here has to be an inverse relationship between DBP and
oronary heart disease (i.e., the lower the DBP the
reater the risk of coronary heart disease). However, this
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The J-Curve November 10, 2009:1827–34tatement does not seem to hold true for cerebrovascular
isease. In the INVEST study there was a significant and
rogressive preponderance of MIs over strokes at low
BP values.
In a reanalysis of the Framingham cohort, Franklin et al.
31) showed that the combined evaluation of SBP and DBP
onferred superior risk prediction over individual compo-
ents; strikingly, only DBP showed a nonlinear, quadratic
elation with CVD risk. For any given SBP, odds of CVD
vents increased in a J-curve fashion at extremes of DBP (odds
atio: 2 to 3). As expected, odds of CVD events increased
onotonically with increasing SBP at any given DBP.
ntihypertensive therapy and J-curve. As mentioned in
he preceding text, the HOT study—in which 18,790
atients were titrated to target DBPs of below 90, below 85,
nd below 80 mm Hg—documented a J-shaped curve in
he 3,000 patients with coronary heart disease in whom the
requency of cardiovascular events/1,000 patient-years was
oughly twice as high compared with the nonischemic group
20,21). Thus, the HOT study establishes a J-curve rela-
ionship between DBP and the risk of MI in patients with
ocumented coronary heart disease (20,21) but not in those
ithout coronary heart disease, a finding akin to that
escribed in the original study of Cruickshank et al. (7).
The 22,576-patient INVEST study was an ideal model to
nalyze the significance of the J-curve, because all patients
ad CAD and hypertension. Indeed, the primary outcome
Figure 1 Incidence of MI and Stroke Stratified by Diastolic Blo
Reproduced with permission from Messerli et al. (29). INVEST  International Vern the INVEST study doubled when DBP was below 70 am Hg and quadrupled when it was below 60 mm Hg. The
adir for DBP was 84 mm Hg. In contrast, the nadir for
BP was 119 mm Hg, and the curve between SBP and
utcome was much shallower than with DBP. Interestingly
nough, in contrast to the risk of acute MI, the risk of stroke
id not increase with low DBP (Fig. 1). Also, patients who
ere revascularized tolerated a lower DBP better than
atients who were not revascularized (Fig. 2).
Lubsen et al. (38), who compared hypertensive subjects
ith normotensive subjects in the ACTION (A Coronary
isease Trial Investigating Outcome with Nifedipine GITS)
rial, concluded that “our data for normotensive subjects are
ompatible with the existence of a J-shaped relationship (or
ore correctly a reverse L-shaped relationship) because in
his sub-group there were nonsignificant trends towards
igher rates of the primary combined endpoints.” More
ecently Protogerou et al. (39), in an elderly population,
gain found a J-shaped curve between cardiovascular death
nd all-cause death and diastolic strata but not SBP strata.
n further analyzing this relationship, the authors concluded
hat “this association was not a simple epiphenomenon
ecause of concomitant chronic illness, cardiac failure or
ncreased arterial stiffness but was associated with reduced
eripheral resistance/pressure wave reflections and poten-
ially aggressive BP reduction, possibly jeopardizing coro-
ary perfusion.” Finally, Fagard et al. (40), in a subanalysis
f the Syst-Eur (Systolic Hypertension in Europe) study,
essure in the INVEST Study
-Trandolapril; MI  myocardial infarction.od Pr
apamillso showed that low DBP with active treatment was
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November 10, 2009:1827–34 The J-Curvessociated with an increased risk of cardiovascular events but
nly in patients with coronary heart disease at baseline.
Although there is substantial evidence to support an
ssociation between antihypertensive therapy and a J-curve
henomenon, a causal relationship has not been established.
Figure 2 Interaction of the J-Curve
With Coronary Revascularization
Patients who were revascularized better tolerate a lower
diastolic blood pressure (DBP) than those who were not.
ummary of Clinical Studies Reporting Association Between Low DTable 1 Summary of Clinical Studies Reporting Association Be
First Author/
Study Name
(Ref. #) Year Subjects (n)
Mean
Age
(yrs)
Mean
Entry DBP
(mm Hg)
Inc
Sub
With
Cruickshank (7) 1987 902 55 109 Y
Fletcher (41) 1988 2,145 51 107 Y
Abernethy (42) 1986 10,053 51 90–104 Y
Waller (43) 1988 3,350 50 110 Y
Coope (44) 1986 884 68 98 Y
Stewart (6) 1979 169 44 124 N
Alderman (45) 1989 1,765 51 102 Y
Staessen (46) 1989 840 71 101 Y
IPPPSH (47) 1985 6,357 52 108 N
ANBP (48) 1981 3,931 50 101 N
Wilhelmsen (49) 1987 6,569 40–60 107 N
Samuelsson (50) 1990 686 52 106 Y
McCloskey (51) 1992 912 30–79 104 Y
Lindblad (16) 1994 2,574 59 92 Y
Somes (33) 1999 4,736 72 77 Y
Hasebe (52) 2002 234 64 88 Y
Pastor-Barriuso (53) 2003 7,830 54 82 N
Zanchetti (54) 2003 18,790 62 100–115 N
Pepine (55) 2003 22,576 66 86 Y
Kannel (36) 2004 7,798 35–80 — N
Lubsen (38) 2005 7,661 63 80 Y
Protegoru (39) 2007 331 85 — Y
Fagard (40) 2007 4,695 70 85 Y
ummary of clinical studies in patients receiving antihypertensive medications and evidence of J-
ANBP Australian National BP Study; CV cardiovascular; CVD cardiovascular disease; DBP diasto
I  myocardial infarction.imilarly, studies with data arguing against the existence of
J-curve have major limitations, such as recording of BP
mmediately before cardiovascular events or other adverse
utcomes. Tables 1 and 2 list clinical studies where data
upport (6,7,16,33,36–55) or refute (19–22) the existence
f a J-curve. It is notable that the end point of MI has the
ost significant association with low DBP, supporting the
ypothesis discussed earlier.
Finally, in a recent commentary on importance of SBP as
target, Williams et al. (56) have invoked the argument that
trials have not shown that a resultant fall in DBP would
mpart harm or off set the benefit of SBP reduction.”
lthough we agree that SBP reduction should be the goal,
aution has to be exercised in lowering the diastolic com-
onent beyond a critical “J-point.” This might be even more
mportant in elderly patients where DBP might already be
educed due to age at onset of therapy.
ntihypertensive Therapy
nd Safety Zone of DBP
he interaction of antihypertensive drugs on BP and coro-
ary hemodynamic status is complex, and head-to-head
omparisons among drugs or drug classes are lacking.
owever, at least 3 different pathophysiologic mechanisms
eserve consideration. First, although all antihypertensive
nd Adverse End PointsLow DBP and Adverse End Points
Mean
Follow-Up
(yrs)
J-Curve Relationship for DBP and Event
J-Point DBP
(mm Hg)MI Stroke
Total Mortality
or Non-CV Events
6.1 Yes No No 85–90 (in ischemic
patients only)
4.0 Yes No No 86–91
4.0 — — Yes *26
6.5 Yes No No 91–98
4.4 Yes — — 80–89
6.3 Yes — — 100–109
4.2 Yes No — 84–88
4.7 Yes Yes Yes 90–95
4.0 Yes — — 92
4.0 Yes Yes — 85–89
3.9 Yes Yes Yes 86–89
12.0 Yes Yes — 81
3–21 Yes No — 84
7.4 Yes — — 90–95
5.0 Yes Yes — 60–65
6.0 Yes — — 95–104
15.0 Yes Yes — 80
3.8 Yes No Yes (in smokers only) 80–85
2.7 Yes Yes Yes 76.4–85.8
10.0 Yes Yes No 80–89
4.9 Yes Yes Yes —
3–4 Yes Yes Yes 70
1–8 Yes Yes Yes *70–75
henomenon. *In patients with coronary artery disease.BP atween
ludes
jects
CVD
es
es
es
es
es
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es
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The J-Curve November 10, 2009:1827–34rugs lower BP, they do not have quantitatively similar
ffects on pulse pressure. Most drug classes, such as blockers
f the renin angiotensin system and calcium antagonists as
ell as the diuretics, improve arterial compliance and thus
ower SBP more than DBP and therefore diminish pulse
ressure. In contrast beta-blockers, because they decrease
eart rate, increase stroke volume and have a less favorable
ffect on pulse pressure than the other drug classes; beta-
lockers (with the notable exception of vasodilating agents
uch as carvedilol and nebivolol) also have been shown to
xert a pseudo-antihypertensive effect in that they lower
eripheral BP more than central pressure. Second, drug
lasses that decrease heart rate allow for more prolonged
iastolic perfusion of the coronary vascular bed. By this
echanism, heart rate-lowering drugs, such as beta-
lockers and some calcium antagonists (verapamil, dilti-
zem), have an advantage over those that do not affect heart
ate. In contrast, antihypertensive drug classes that acceler-
te heart rate might have a detrimental effect on coronary
erfusion. Indeed, short-acting calcium antagonists and
ther arteriolar vasodilators (i.e., hydralazine, minoxidil) are
rone to cause myocardial ischemia in susceptible patients
4). Third, antihypertensive drug classes that reduce LVH
nd hypertensive vascular disease are more effective over the
ong term in improving coronary flow reserve than drug
lasses that have little or no effect. Thus, blockers of the
enin angiotensin system, calcium antagonists as well as the
iuretics, have been shown to reduce LV hypertension (57)
nd hypertensive vascular disease (58–60) and improve
rterial compliance (61) better than beta-blockers. Drugs
hat improve arterial compliance slow the reflected wave so
t might supplement coronary filling during diastole rather
han arrive during systole and increase cardiac workload.
onclusions
umerous studies have documented an inverse relationship
etween DBP and coronary heart disease (i.e., a J-shaped
urve). In most studies, the J-shaped curve was found to be
n the physiologic range at levels of DBP below 70 to 80
m Hg. At the same reduced DBP levels, there is little if
ny evidence of a J-shaped curve with regard to other target
rgans, such as the brain and the kidney. Moreover, few if
ny J-shaped curve phenomena have been documented
ummary of Clinical Studies Reporting No Clear Association Betwend Adverse End Poin s But Upon Further Inspection of Data PointTable 2 Summary of Clinical S udies Reporting N Clear Assocand Adverse End Points But Upon Further Inspection o
First Author/
Study Name
(Ref. #) Year
Subjects
(n)
Mean
Age (yrs)
Mean
Entry DBP
(mm Hg)
Includ
Wi
Hansson (20) 1998 18,790 62.0 105.0
Psaty (22) 2001 4,902 72.6 71.0
Glynn/PHS (19) 2002 22,071 53.2 78.8
Glynn/WHS (19) 2002 39,876 53.8 77.7
In patients with ischemia.
PHS  Physician’s Health Study; WHS  Women’s Health Study.etween systolic pressure and coronary, renal, or cerebro-
1ascular events. However, careful scrutiny of the available
ata seems to show a J-shaped relationship between DBP
nd coronary heart disease in high-risk patients. These are
ften characterized by being elderly, having LVH and/or
oronary heart disease, and by exhibiting a wide pulse
ressure.
Thus, there might be more than just a semantic reason for
ypertension to remain “essential”; this seems to be partic-
larly true for DBP in patients with CAD. Unfortunately,
he arguments surrounding the J-curve phenomenon have
ften become unnecessarily contentious. However, these
onsiderations should not deter practicing physicians from
ursuing more aggressive control in treating hypertension,
ecause currently, at best, only approximately one-third of
ur patients are at goal BPs of 140/90 mm Hg (62).
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